Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06347705 · ClinicalTrials.gov registry record · Phase 2

A Study of 2141-V11 in Combination With Standard Treatments in People With Prostate Cancer

A Phase 2 study of Prostate Cancer, sponsored by Memorial Sloan Kettering Cancer Center.

Recruiting
Registry status
Phase 2
Development phase
99
Enrollment target
7
Study locations

NCT06347705: Recruiting Phase 2 study of Prostate Cancer, sponsored by Memorial Sloan Kettering Cancer Center.

NCT06347705 is a Phase 2 study of Prostate Cancer that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 99 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (84% lower). The trial reports 7 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06347705, a Phase 2 study of Prostate Cancer, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.

RECRUITING
Registry status
Phase 2
Development phase
99 participants
Enrollment target
7
Study locations

Study Summary

The purpose of this study is to see whether combining 2141-V11 with various standard treatments is an effective treatment approach for prostate cancer. 2141-V11 works by activating the immune system to find and kill cancer cells. Researchers will look at whether this treatment approach is able to completely get rid of cancer in participants, and they will check for the presence of minimal residual disease (MRD) in participants. MRD is a small number of cancer cells that can be detected in the body after treatment.

Conditions Studied

Prostate Cancer

Interventions

  • BIOLOGICAL 2141-V11 Antibody

Study Locations (7)

New York

  • Memorial Sloan Kettering Suffolk-Commack (Limited protocol activity) - Commack
  • Memorial Sloan Kettering Westchester (Limited Protocol Activities) - Harrison
  • Memorial Sloan Kettering Cancer Center (All protocol activites) - New York
  • Memorial Sloan Kettering Nassau (Limited Protocol Activites) - Rockville Centre

New Jersey

  • Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) - Basking Ridge
  • Memorial Sloan Kettering Monmouth (Limited protocol activities) - Middletown
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale

Trial Details

FieldValue
Enrollment Target 99 participants
Start Date 2024-03-28
Est. Completion 2029-03-28
Phase Phase 2

Sponsor

Memorial Sloan Kettering Cancer Center

1,884 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06347705

The ClinicalTrials.gov registry entry for NCT06347705 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (84% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which 2141-V11 Antibody is the first listed.

NCT06347705 reports 7 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.

Frequently Asked Questions

What is clinical trial NCT06347705 about?

NCT06347705 is a clinical study titled "A Study of 2141-V11 in Combination With Standard Treatments in People With Prostate Cancer". The purpose of this study is to see whether combining 2141-V11 with various standard treatments is an effective treatment approach for prostate cancer. 2141-V11 works by activating the immune system to find and kill cancer cells. Researchers will look at whether this treatment approach is able to co...

What is the current status of trial NCT06347705?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 99 participants. The study started on 2024-03-28. Estimated completion is 2029-03-28.

What conditions does trial NCT06347705 study?

This clinical trial studies the following conditions: Prostate Cancer.

What interventions are being tested in trial NCT06347705?

The interventions under investigation include: 2141-V11 Antibody (BIOLOGICAL).

Who is sponsoring clinical trial NCT06347705?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06347705 being conducted?

This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Prostate Cancer

All registered trials for this condition

New Jersey

All trials with a study site in New Jersey

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.